

RESTRICTION PRESENTED

The claims have been restricted into the following groups of inventions:

<u>Groups</u>	<u>Claims</u>	<u>Subject Matter</u>
I	1-12 and 45-54	Methods of screening candidate substances for an ability to modulated phosphatidylserine exposure on the surface of a cell or platelet VDCC subunit biological activity by using a test sample comprising a VDCC subunit and a cell line suitable therefor, classified in class 435, subclass 7.2.
II	13-14	Methods of screening candidate substances for an ability to modulated phosphatidylserine exposure on the surface of a cell by using a test sample comprising a transcriptional regulatory sequence, classified in class 536, subclass 24.1.
III	15-22	Method of modulation by administering a substance to a cell, classified in class 435, subclass 325, for example.
IV	23-24	Pharmaceutical compositions for modulating phosphatidylserine exposure, classified in class 514, subclass 12, for example.
V	25-30	Method of modulating phosphatidylserine exposure by administering a recombinant polynucleotide construct to the cell, classified in class 514, subclass 44, for example.
VI	31-37	Method of modulating thrombosis by administering a substance, classified in class 514, subclass 12, for example.
VII	38	Pharmaceutical composition for modulating thrombosis, classified in class 514, subclass 12, for example.
VIII	39-44	Method modulating thrombosis in a subject by gene therapy, classified in class 514, subclass 44, for example.
IX	55-56	Method of screening candidate substances for an ability to modulate platelet VDCC biological activity using a transcriptional regulatory sequence, classified in class 536, subclass 24.1.

Application Serial No.: 10/726,216

- | | | |
|------|-------|--|
| X | 57-61 | Method of modulating platelet VDCC biological activity by administering a substance, classified in class 435, subclass 325, for example. |
| XI | 65-66 | Pharmaceutical composition for modulating platelet VDCC biological activity, classified in class 514, subclass 12, for example. |
| XII | 67-72 | Method of modulating calcium transport, classified in class 514, subclass 44, for example. |
| XIII | 73-76 | Method of modulating apoptosis, classified in class 435, subclass 325, for example. |
| XIV | 77-78 | Method increasing storage life of a cell, classified in class 435, subclass 325, for example. |

APPLICANTS' ELECTION

Applicants hereby elect the invention of Group I, claims 1-12 and 45-54, drawn to methods of screening candidate substances for an ability to modulated phosphatidylserine exposure on the surface of a cell or platelet VDCC subunit biological activity by using a test sample comprising a VDCC subunit and a cell line suitable therefor, for prosecution at this time. Applicants hereby reserve the right to file one or more divisional application(s) directed to the unelected subject matter.

REMARKS

Claims 1-78 are now pending in the subject U.S. patent application. Claims 1-78 as filed have been subjected to a Restriction/Election Requirement.

In response to the Restriction/Election Requirement, applicants have elected the claims of Group I, claims 1-12 and 45-54, for prosecution at this time.

CONCLUSIONS

Should there be any minor issues outstanding in this matter, the Examiner is respectfully requested to telephone the undersigned attorney. Early passage of the subject application to issue is earnestly solicited.

Application Serial No.: 10/726,216

Deposit Account

The Commissioner is hereby authorized to charge any deficiency in payment or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date: November 7, 2006

By:


Arles A. Taylor, Jr.

Registration No. 39,395

421/29/2/2 AAT/_CPP/ljp

Customer No: 25297